Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma

被引：39
|
作者：
Allmeroth, Kira [1 ]
Horn, Moritz [2 ]
Kroef, Virginia [1 ]
Miethe, Stephan [1 ]
Mueller, Roman-Ulrich [3 ,4 ,5 ,6 ]
Denzel, Martin S. [1 ,3 ,6 ]
机构：
[1] Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany
[2] Acus Labs GmbH, Max Planck Inst Biol Ageing, Joseph Stelzmann Str 9b, D-50931 Cologne, Germany
[3] Univ Cologne, CECAD Cluster Excellence, Joseph Stelzmann Str 26, D-50931 Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Internal Med 2, Kerpener Str 62, D-50937 Cologne, Germany
[5] Univ Cologne, Univ Hosp Cologne, Kerpener Str 62, D-50937 Cologne, Germany
[6] Univ Cologne, Ctr Mol Med Cologne CMMC, Robert Koch Str 21, D-50931 Cologne, Germany
来源：
LEUKEMIA | 2021年 / 35卷 / 03期
关键词：
20S PROTEASOME;
D O I：
10.1038/s41375-020-0989-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：887 / 892
页数：6
相关论文
共 48 条
  • [31] Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis
    Verbrugge, Sue Ellen
    Assaraf, Yehuda G.
    Dijkmans, Ben A. C.
    Scheffer, George L.
    Al, Marjon
    den Uyl, Debby
    Oerlemans, Ruud
    Chan, Elena T.
    Kirk, Christopher J.
    Peters, Godefridus J.
    Van der Heijden, Joost W.
    de Gruijl, Tanja D.
    Scheper, Rik J.
    Jansen, Gerrit
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (01): : 174 - 182
  • [32] Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
    Plakoula, Eva
    Kalampounias, Georgios
    Alexis, Spyridon
    Verigou, Evgenia
    Kourakli, Alexandra
    Zafeiropoulou, Kalliopi
    Symeonidis, Argiris
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2025, 47 (01)
  • [33] DOWNREGULATION OF TELOMERASE ACTIVITY IN RESPONSE TO NEW GENERATION OF PROTEASOME INHIBITORS (EPOXOMICIN AND MG132) IN MULTIPLE MYELOMA CELLS
    Muchtar, E.
    Uziel, O.
    Shalem, N.
    Beery, E.
    Nordenberg, Y.
    Bakhanashvili, M.
    Gutkin, A.
    Lahav, M.
    HAEMATOLOGICA, 2014, 99 : 100 - 100
  • [34] Acquired Resistance to Bortezomib in Human RPMI-8226 Multiple Myeloma Cells: Molecular Characterization, Cross-Resistance with Other Proteasome Inhibitors but Marked Sensitization to Glucocorticoids
    Franke, Niels E.
    Kaspers, Gertjan L.
    van den Berg, Nynke
    van Zantwijk, Ina
    Vojtekova, Katarina
    Yaqub, Uzma
    Smeets, Serge
    Ylstra, Bauke
    Zweegman, Sonja
    Jansen, Gerrit
    Cloos, Jacqueline
    BLOOD, 2008, 112 (11) : 913 - 913
  • [35] THE RESISTANCE TO PROTEASOME INHIBITORS IS MEDIATED BY OVERACTIVATION OF THE UNFOLDED PROTEIN RESPONSE (UPR) AND THE RESPONSE MECHANISM TO DNA DAMAGE IN PRECLINICAL MODEL OF MULTIPLE MYELOMA
    Susana, Hernandez-Garcia
    Lorena, Gonzalez-Mendez
    Dalia, Quwaider
    Noemi, Puig
    Esperanza M, Algarin
    Ana Alicia, Lopez-Iglesias
    Laura, San-Segundo
    Montserrat, Martin-Sanchez
    Teresa, Paino
    Ana Belen, Herrero
    Irena, Misiewicz-Krzeminska
    Maria Victoria, Mateos
    Norma C, Gutierrez
    Mercedes, Garayoa
    Enrique M, Ocio
    HAEMATOLOGICA, 2016, 101 : 20 - 21
  • [36] Spliced XBP1 Levels Determine Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitor Bortezomib Independent of the Unfolded Protein Response Mediator GRP78
    Borjan, Bojana
    Kern, Johann
    Steiner, Normann
    Gunsilius, Eberhard
    Wolf, Dominik
    Untergasser, Gerold
    FRONTIERS IN ONCOLOGY, 2020, 9
  • [37] Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles
    Goethals, Olivia
    Vos, Ann
    Van Ginderen, Marcia
    Geluykens, Peggy
    Smits, Veerle
    Schols, Dominique
    Hertogs, Kurt
    Clayton, Reginald
    VIROLOGY, 2010, 402 (02) : 338 - 346
  • [38] Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma
    Xing, Lijie
    Lin, Liang
    Yu, Tengteng
    Li, Yuyin
    Wen, Kenneth
    Cho, Shih-Feng
    Hsieh, Phillip A.
    Kinneer, Krista
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Tai, Yu-Tzu
    BLOOD, 2019, 134
  • [39] MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma
    Tai, Yu-Tzu
    Xing, Lijie
    Lin, Liang
    Yu, Tengteng
    Cho, Shih-Feng
    Wen, Kenneth
    Kinneer, Krista
    Munshi, Nikhil
    Anderson, Kenneth C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E154 - E155
  • [40] Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations
    Saladini, Francesco
    Giannini, Alessia
    Boccuto, Adele
    Dragoni, Filippo
    Appendino, Alice
    Albanesi, Edoardo
    Vicenti, Ilaria
    Zazzi, Maurizio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (01)
12345